Objective: The effect of prophylactic administration of a selective endothelin A receptor antagonist (ET A -RA) on ischemia/reperfusion injury in an experimental model of graft pancreatitis after pancreas transplantation was evaluated. Summary Background Data: It is well established that endothelin-1 (ET-1), a powerful vasoconstrictor, plays an important role in the development of pancreatitis. Recent studies have shown a beneficial effect of endothelin receptor antagonists in the therapy for experimental pancreatitis. Methods: Relevant ischemia/reperfusion injury was induced in pig pancreas transplants after 6 hours hypothermic preservation in University of Wisconsin solution. The recipients were randomized into 2 groups: control pigs received isotonic saline and the treated group received the selective ET A -RA BSF 208075 at the beginning of reperfusion. On postoperative days 2 and 5, animals were relaparotomized to obtain tissue specimens. Blood monitoring included lipase, amylase, C-reactive protein, trypsinogen-activation peptide, thiobarbituric acid-reacting substances, and ET-1. Partial oxygen tension (p ti O 2 ) was measured by a Clarke-type electrode and blood flow by laser doppler. A semiquantitative score index was used for assessment of histologic injury and for immunohistochemical analysis of ET-1 and ET A receptor expression. Tissue mRNA levels of prepro ET-1, ET A receptor, pro-interleukin (IL)-6, and pro-IL-1␤ were quantified using TaqMan real-time reverse transcription-polymerase chain reaction (RT-PCR). Results: Prophylactic treatment with ET A -RA significantly reduced the severity of graft pancreatitis evidenced by C-reactive protein.
T he most successful approach for restoring normal longterm glucose homeostasis in type I diabetes mellitus is whole-organ pancreas transplantation. 1 Graft pancreatitis is an infrequent but potentially fatal complication. It occurs as a result of cold storage and reperfusion injury. Depending on its severity, ischemia/reperfusion injury causes functional deterioration, local and systemic complications, and is responsible for up to 7% of organ losses. 2 Postischemic tissue injury after experimental and human pancreas transplantation is characterized by a disturbance of the pancreatic microcirculation which leads to secondary ischemia. [3] [4] [5] In a model of syngeneic pancreas transplantation in rats, the microcirculatory disturbances and cellular damage are similar to those seen in the beginning of an acute pancreatitis. 5 Based on the concept of microcirculatory impairment as a major determinant of ischemia/reperfusion injury, improving microcirculation appears to be a logical approach to therapy. The pathogenesis of these microcirculatory disorders is multifactorial and involves vasoactive mediators. An essential mechanism is the imbalance between the 2 strongest vasoactive mediators, endothelin-1 (ET-1) and nitric oxide (NO). 6, 7 ET-1, which is the most abundant and potent member of the endothelin family, was originally isolated from cul-tured porcine endothelial cells and was found to be a powerful vasoconstrictor. 8 It is a peptide with 21 amino acids and is produced by ischemic or injured endothelial cells. The effects of ET-1, which acts mainly in a paracrine manner, are mediated by 2 receptor subtypes, designated ET A and ET B . 8, 9 ET A receptors mediate vasoconstriction and ET B receptors mediate primarily NO-dependent vasodilation. Several previous studies have shown a beneficial effect of endothelin receptor antagonists in the therapy for experimental not primarily ischemia/reperfusion induced pancreatitis when administered hours after onset of disease. 6,10 -13 These studies imitated the clinical situation of human acute pancreatitis in which the therapy usually begins several days after disease onset. However, prophylactic treatment is possible in the setting of acute graft pancreatitis after transplantation. Up to the present, no study has assessed the effectiveness of a selective ET A receptor antagonist (ET A -RA) in preventing ischemia/ reperfusion injury in the context of pancreas transplantation. The aim of the present study was to investigate if the prophylactic administration of a selective ET A -RA at the beginning of reperfusion has an effect on microcirculation, histology, immunohistochemical and mRNA expression of vasoactive mediators and biochemical alterations. We used a pig model that closely resembles clinical pancreas transplantation.
MATERIALS AND METHODS

Experimental Protocol
The investigation was performed in accordance with the German legislation on protection of animals and the experiments were approved by the Committee on Animal Care (Regierungspräsidium, Leipzig, Germany; No. 02/00). Twenty-eight female Göttingen Minipigs (Ellegaard Göttingen Minipigs ApS, Denmark) weighing 20 -25 kg were used either as donors (n ϭ 14) or as recipients (n ϭ 14). The recipients were randomized into 2 groups: the control group (n ϭ 7) received 50 mL of isotonic saline solution iv, and the therapy group (n ϭ 7) received the specific ET A receptor antagonist BSF 208075 (ET A -RA) provided by Knoll AG, Ludwigshafen, Germany. We chose a ET A -RA dosis of 10 mg/kg iv according to the references in the literature and the manufacturer's recommendations. The ET A -RA was administered as continuous intravenous infusion during the first 30 minutes of reperfusion. At day 2 and 5 after surgery, the animals underwent relaparotomy to determine the histologic damage. Thereafter, the animals were killed.
Transplantation Model
Twenty-four hours before and after surgery the food intake of the animals was restricted with free access to water. Azaperon (15 mg/kg iv; Stresnil, Cilag-Janssen, Neuss, Germany), atropin (0.2 mg/kg iv; Atropinsulfat, Braun, Melsungen, Germany), and ketanest (3 mg/kg iv; Ketamin, Ratio-pharm, Ulm, Germany) were administered for premedication. The anesthesia was induced with thiopental (8 mg/kg iv; Trapanal; Byk Gulden, Konstanz, Germany) and maintained with isoflurane (Forene, Abbott, Wiesbaden, Germany). Ventilation was performed with the respirator "Julian" (Draegerwerk AG, Luebeck, Germany) with a F i O 2 of 40%.
A composite graft, including the whole pancreas and part of the duodenum, was harvested from the donor pig. Immediately after harvesting, the graft was perfused with University of Wisconsin solution (Viaspan, DuPont Pharma GmbH, Bad Homburg, Germany) via the aortic patch until clear fluid returned from the portal vein. A maximum perfusion pressure of 100 mm Hg was used. The graft was prepared in cold saline solution at ϩ4°C. The duodenal segment was shortened to approximately 10-12 cm using a proximate PLC 50 stapler (Ethicon, Norderstedt, Germany). A patch of the aorta including the celiac axis and the superior mesenteric artery was used for arterial supply and the portal vein served for venous drainage from the pancreas. The graft was then stored for 6 hours in UW solution at ϩ4°C.
The recipient pig was provided with a central venous catheter in the external jugular vein which was then subcutaneously tunneled to the back of the neck. Another catheter was placed in the carotid artery for continuous blood pressure monitoring. After inducing anesthesia, a bolus of 500 mg methylprednisolone (Urbason, Hoechst, Frankfurt, Germany) and antibiotic prophylaxis with mezlocillin (Baypen, Bayer, Germany) was given intravenously. The graft was placed intraperitoneally in the recipient. The venous anastomosis was performed between the portal vein of the graft and the distal vena cava, the arterial anastomosis between the donor aortic patch and the infrarenal aorta. Using enteric drainage, the duodenal segment was sutured to the ileum in a two-layer side-to-side anastomosis.
Immunosuppression
Immunosuppression consisted of 6 mg/kg/day cyclosporine A (Sandimmune, Novartis, Nuernberg, Germany) given by short-term intravenous infusion (30 minutes) and 1 mg/kg/d iv of prednisolone (Prednisolut, Jenapharm, Jena, Germany), beginning on the first postoperative day. The cyclosporine A dose was adjusted to achieve a blood trough concentration of 150 -200 ng/ml. Cyclosporine levels were determined using the EMIT 2000 cyclosporine-specific assay (Dade Behring Inc., Deerfield, IL). This test uses a homogeneous enzyme immunoassay technique that requires 100 L of whole blood. many) into the corpus of the pancreas. Tissue p ti O 2 was measured in the donor for 30 minutes before organ harvesting and in the recipient for 1 hour beginning immediately before onset of reperfusion and on the second and fifth postoperative day.
Laser Doppler Flow Measurement
Blood flow was measured by placing the Doppler flow probe (DP 1) at 3 different points of the pancreas and duodenum: (1) the tail of the pancreas, (2) the head of the pancreas, and (3) the duodenum. The measurements were performed in the donors before organ harvesting and in the recipients 30 and 90 minutes after reperfusion and were monitored on a Moor Instruments DRT4 Monitor (Moor Instruments, Devon, UK). The principle of the probe is that light generated by a laser diode (780-nm wavelength with maximal emission energy of 1.0 mW) penetrates the tissue, where it is reflected by circulating blood cells. Analog laser Doppler flow signals were digitalized and processed on a personal computer with the DRTSOFT V2.9 software (Moor Instruments). Blood flow was recorded for at least 30 seconds after obtaining a stable signal. It was measured in perfusion units, an arbitrary unit that compares erythrocyte flux in sample volume with the random temperature-dependent motion of polystyrene microspheres in a calibration solution. Postsampling data processing included analysis with integral under the curve. For integral estimation, the mean of the pulse waves within the 30 seconds sampling period was calculated.
Blood Measurements
Serum lipase, amylase, and CRP were measured on an automatic analyzer (Hitachi 917). Trypsinogen activation peptide (TAP) concentrations were determined with a quantitative competitive enzyme-linked immunosorbent assay, 14, 15 based on the competition between free and immobilized peptide binding to an affinity-purified rabbit antibody to TAP (TAPKIT, Biotrin International Ltd., Dublin, Ireland). Plasma ET-1 levels were determined in EDTA plasma using the QuantiGlo ET-1 Chemiluminescent Immunoassay (R&D-Systems, Nivelles, Belgium). There was no crossreactivity of the antibody used to quantify ET-1 with the ET A -RA. The formation of thiobarbituric acid reacting substances (TBARS) was measured as a surrogate marker of oxidative stress. 16 
Light Microscopy
Specimens taken from the corpus of the pancreas were fixed in 4% formaldehyde, embedded in paraffin, sectioned and stained with hematoxylin/eosin. Development of interstitial edema was quantitatively assessed by planimetric analysis (area measurement, given in percent of the complete area under investigation) using a computer-assisted image analysis system (CapImage; Zeintl, Heidelberg, Germany). 6 Leukocyte infiltration into tissue was analyzed histomorphologically by counting the number of polymorphonuclear cells in 50 high-power fields. The numbers were scored using a classification system from 0 (no infiltration) to 3 (severe). Likewise, hemorrhagic injury, exocrine and endocrine cell necrosis and quality of interstitial blood vessels were documented using a scoring system from 0 (no pathologic changes) to 3 (severe injury). An overall score per animal and time of investigation was calculated by adding together the results of the individual parameters of injury.
Immunohistochemical Analysis of ET-1 and ET A Receptor
For immunohistochemical analysis of ET-1 and ET A receptor, the tissue was routinely fixed in 4% formaldehyde solution and embedded in paraffin. Sections (4 m thick) were cut, dewaxed in xylene, and then rehydrated. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in phosphate-buffered saline (PBS) for 20 minutes. After a short rinse with PBS, the sections were boiled in citrate buffer for 15 minutes in microwave (600 watt). After cooling, the sections were covered with normal goat serum for 20 minutes and then incubated with the primary antibody against ET-1 or ET A receptor (DPC Biermann, Bad Nauheim, Germany). The sections were washed with PBS, incubated with biotinylated goat antirabbit immunoglobulin G (Bio-Genex R, Hamburg, Germany) for 30 minutes, and covered with peroxidase-conjugated streptavidin (BioGenex R, Hamburg, Germany). The peroxidase reaction was allowed to proceed for 5 minutes, with 3-amino-9-ethylcarbazole solution as substrate. Slides were counterstained with Meyer's hemalum and finally mounted. The intensity of intracytoplasmic ET-1 and membrane ET A receptor immunostaining was graded semi-quantitatively from 0 (no staining) to 3 (maximal intensity of staining). The number of positive cells was counted and scored semiquantitatively from 0 to 4 (0 ϭ 0; 1 ϭ 1-30; 2 ϭ 31-60; 3 ϭ 61-90; 4 Ն 90 stained cells in 1 of 10 observed areas). Negative controls were included in each batch replacing the primary antibody. An overall score per animal and time of investigation was calculated by multiplying the value for intensity of immunostaining by the score of positive cells.
Electron Microscopy
Fixation was performed using glutaraldehyde plus paraformaldehyde. Specimens were cut into small pieces and subjected to further fixation with 2% osmium tetroxide in Millonig buffer. Subsequently, the tissue was dehydrated in graded alcohol and embedded in Epon resin. Ultrathin sections were contrasted with uranyl acetate and lead citrate and examined using a transmission electron microscope (EM 900, Zeiss, Germany). Histologic, immunohistochemical analysis, and electron microscopy were performed independently by 3 investigators (B.A., A.T., D.U.) who were blinded to clinical and pathologic information. 
TaqMan Real-Time RT-PCR
Total RNA was isolated using the monophasic phenolguanidine isothiocyanate Trizol reagent (Invitrogen, Groningen, NL). To avoid degradation of RNA during the isolation procedure, 1 L/ RNase inhibitor was added to 1 mL of Trizol reagent. cDNA was prepared from 1 g of total RNA by RT with SuperScript II RNase H-reverse transcription (Invitrogen, Karlsruhe, Germany) using random hexamer primers p(dN) 6 (Roche Diagnostics GmbH, Mannheim, Germany).
TaqMan-primers and probes for ␤-actin, preproendothelin-1, ET A receptor, pro-interleukin (IL)-1␤ and pro-IL-6 were designed from published porcine mRNA sequences (GenBank accession numbers: U07786, X07383, S80652, M86725, M86722).
The following primers were used: Primers and probes were selected to span 2 exons to prevent amplification of putative contaminations with genomic DNA. The probes were labeled with 6-carboxyfluorescein as a reporter dye at the 5'-end and 6-carboxytetramethylrhodamine as a quencher dye at the 3'-end. The TaqMan PCR was prepared in a final volume of 25 L containing 5 L of cDNA (diluted 1:10), 25 mM MgCl 2 , 2.5 L 10ϫ Amplitaq buffer A, 200 M dNTP (each), 1.25 U Amplitaq Gold (Perkin-Elmer Applied Biosystems, Foster City, CA), 200 nM fluorescently labeled oligonucleotide probe, and 900 nM of each oligonucleotide primer. The PCR was performed in an ABI PRISM 7700 Sequence Detector (Perkin-Elmer Applied Biosystems, Foster City, CA) with continuous monitoring of fluorescence. The PCR conditions were 2 minutes at 50°C followed by an initial denaturation at 95°C for 10 minutes and 40 2-step cycles of 95°C for 15 seconds; 60°C for 1 minute. A standard curve was constructed using a serial dilution of known copy numbers of cDNA fragments of the respective target genes cloned into the PCR-TOPO vector (Invitrogen, Inchinnan, UK). ␤ actin was used as an internal standard in each experiment.
Statistical Analysis
Data were expressed as means Ϯ SD. Histologic and immunohistochemical scores of injury were represented in the form of "box whisker plots" showing the median value, the 25th and 75th percentiles and 95th percentiles. Variables were tested for group differences with the Mann-Whitney U test. P Ͻ 0.05 was considered significant. Statistical calculations were performed with the SigmaPlot 2001 software package (SPSS Inc., Chicago, IL).
RESULTS
Tissue Oxygenation
The mean p ti O 2 levels of the donor groups were not significantly different (control vs. therapy group: 54.2 Ϯ 9.6/52.2 Ϯ 9.6 mm Hg). In the recipients, the levels dropped at the end of cold ischemic time to 0-1 mm Hg in both groups. After reperfusion, the mean p ti O 2 level in the control group increased to 42.8 Ϯ 5.5 mm Hg after 10 minutes but decreased again to 24.9 Ϯ 6.3 mm Hg 30 minutes and to 20.1 Ϯ 3.5 mm Hg 60 minutes after reperfusion (P Ͻ 0.05 vs. 10 minutes after reperfusion). On the second and fifth postoperative day, a slight but not significant increase of the p ti O 2 values was observed. In the therapy group, a similar graph was seen but the corresponding mean p ti O 2 values were found to be significantly higher (P Ͻ 0.05) at each measurement point compared with the control group. In comparison to the preischemic p ti O 2 levels in the donors, the values in the control group were significantly lower, whereas the corresponding levels of the therapy group did not differ at any time with a maximum peak at 10 minutes ( Fig. 1 ).
Laser Doppler Flow Measurement
The results are summarized in Table 1 . In the donors, the integrals under the curve revealed no significant differences between the control and therapy group at all measurement points. In both donor groups the values were significantly higher in the duodenum than in the head and the tail of the pancreas (P Ͻ 0.05). Thirty minutes after reperfusion, a significant decrease of blood flow compared with the preischemic levels was found at all measurement points in the control group and in the duodenum of the therapy group only. No relevant changes of blood flow were seen 90 minutes as compared with 30 minutes after reperfusion within the control and therapy group except for a significant increase in the duodenum of the therapy group (P Ͻ 0.05). When the control and therapy group were compared, a significant difference in blood flow was observed 30 and 90 minutes after reperfusion in favor of the treatment group at all measurement points (P Ͻ 0.05). There was no significant difference in blood flow between the 3 measurement points 30 minutes after reperfusion in the 2 groups. At the 90 minutes time point blood flow did not differ between the 3 parts of the graft in the control group whereas significantly higher values were found in the duodenum versus head and tail in the treated group, analogous to the situation in the donors. 
Lipase, Amylase, CRP, TAP, Oxygen Radicals
Plasma ET-1
The mean ET-1 values in the central venous blood of the recipients did not differ between the 2 groups before surgery. Immediately before reperfusion, the levels in both groups were significantly higher as compared with the baseline without difference between the groups. After reperfusion, a further significant increase to the maximum of 3.48 Ϯ 1.09 pg/mL (P Ͻ 0.05) at 2 hours was measured in the control group. In the therapy group, a marked increase to the maximum level of 33.1 Ϯ 7.4 pg/mL (P Ͻ 0.05) at 1 hour after reperfusion was seen. On the second and fifth postoperative day in the 2 groups similar ET-1 levels than before reperfu- sion were observed. In the period from 30 minutes to 12 hours, significantly higher ET-1 values were measured in the treated group in comparison to the control group (P Ͻ 0.05; Fig. 2 ). 30 minutes after reperfusion, there was no difference in the 2 groups between the ET-1 levels of the central venous blood and the portal venous blood of the graft.
Histology
Before organ procurement, there was no evidence of morphologic damage in either donor group. At the end of the cold ischemic time, a slight increase of injury was seen without difference between the 2 groups. After reperfusion, the histologic injury score increased in both groups, but was found to be significantly lower in the therapy group 10 minutes (P Ͻ 0.05), 1 hour (P Ͻ 0.05), 2 days (P Ͻ 0.05), and 5 days (P Ͻ 0.05) after reperfusion ( Fig. 3 ). Severe exocrine cell necrosis and interstitial edema was observed in 2/7 animals of the control group and in none of the treated group. A severe leukocyte reaction was seen in 4 untreated and in none of the treated animals. The histomorphological alterations were found to be almost homogeneously distributed over the entire pancreas, ie, the head, corpus and tail of the gland.
Electron Microscopy
In accordance with light microscopic findings, the therapy group showed only a mild interstitial edema 1 hour after reperfusion. At this time, the first signs of pancreatic injury appeared in the control group, such as swelling and dilatation of the endoplasmic reticulum, vacuolization, and loss of zymogen granules. On the second postoperative day, a marked increase of acinar cell injury with vacuolar degeneration, dilatation of endoplasmic reticulum, damage of mitochondria, disintegration of nuclei with large clusters of chromatin adjacent to the nuclear membrane, and fusion of zymogen granules were observed in the control group. In addition, several apoptotic bodies were visible and granulocytes and macrophages were observed adjacent to those areas. In the therapy group, cells appeared to be almost normal on the second postoperative day except for a mild interstitial edema and a slight cytoplasmic vacuolization.
Immunohistochemical Analysis
In the donors no or only focal presence of ET-1 immunoreactivity was found in either group. At the end of the cold ischemic time, we observed a faint, intracytoplasmic immunoreactivity in vascular endothelial cells, endocrine cells of Langerhans islets and exocrine acinar cells that was comparable in the 2 groups. Ten minutes and 1 hour after reperfusion, the median ET-1 levels showed a relevant increase in the control group only and were significantly higher as compared with the therapy group (P Ͻ 0.05). On the fifth FIGURE 2. Mean plasma endothelin-1 (ET-1) values of the recipients given endothelin-A receptor antagonist (therapy group) or saline (control group). Values are means Ϯ SD. Administration of the specific endothelin-A receptor antagonist led to significant higher ET-1 levels as compared with the control group during the period from 30 minutes to 12 hours after reperfusion. *, therapy group vs. control group, P Ͻ 0.05. **, before reperfusion vs. baseline, P Ͻ 0.05 (control and therapy group). ***, two hours after vs. before reperfusion, P Ͻ 0.05 (control and therapy group).
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Endothelin A Receptor Antagonist in Pig Pancreas Transplantation postoperative day, very few ET-1 positive cells similar as before surgery were seen in either group (Fig. 4) . The values of the ET A receptor immunoreactivity showed a curve similar to that of ET-1 during procurement and transplantation. ET A receptor expression was significantly higher in the control group 10 minutes (P Ͻ 0.05), 1 hour (P Ͻ 0.05), and 2 days (P Ͻ 0.05) after reperfusion as compared with the treated group (Fig. 5 ).
Prepro ET-1, ET A , Pro-IL-6, and Pro-IL-1␤ mRNA Expression
Quantitative RT-PCR 60 minutes after reperfusion revealed a significant up-regulation of prepro ET-1 (P Ͻ 0.05) and pro-IL-6 (P Ͻ 0.05) in nontreated recipients as compared with the baseline levels of the donors. In contrast, ET A receptor expression showed a significant downregulation (P Ͻ 0.05). Pro-IL-1␤ mRNA levels were not significantly affected. Treat-ment with the selective ET A -RA resulted in significantly lower prepro ET-1 (P Ͻ 0.05) and IL-6 (P Ͻ 0.05) levels and a relevant up-regulation of ET A receptor expression (P Ͻ 0.05) as compared with the control group. The difference in pro-IL-1␤ mRNA concentrations between the 2 groups did not reach statistical significance (Fig. 6 ).
DISCUSSION
The pancreas has intrinsically a low blood flow compared with other solid organs and is highly susceptible to ischemic injury and hypoperfusion. In pancreas transplantation, ischemia/reperfusion as the only insult to a normal pancreas is considered to be the initiating factor of graft pancreatitis. ET-1 plays a crucial regulatory role in the microcirculation of the pancreas. 10, 17, 18 It does not only mediate local injury, but also systemic disease. 10 The deleterious effects of ET-1 result from its vasoactive properties and other not yet completely understood mechanisms such as its influence on the release of proinflammatory cytokines by monocytes. 19, 20 The significant increase of ET-1 in the control group of our series indicates its important role in graft pancreatitis. In recent reports, a protective effect of endothelin receptor antagonists on primary ischemia/reperfusion injury of the liver, 21-23 kidney, 24 and small bowel 25 has been reported. In the present study, it could be clearly shown for the first time that endothelin-A receptor blockade performed in a prophylactic design significantly reduces ischemia/reperfusion injury in pancreas transplantation. The dramatic increase of ET-1 in the treated group is clear evidence of effective receptor blockade by ET A -RA BSF 208075, which agrees with the findings of Foitzik et al. 6 The rationale for administration the ET A -RA to the recipients at the beginning of reperfusion was the concept that the first minutes after reperfusion seem to be particularly important for the manifestation of ischemia/reperfusion injury. 26 Furthermore, the rationale included the phenomenon of early transient reperfusion after pancreatic ischemia, during which time prophylactic treatment of microcirculation is possible. 27, 28 Another point is, that in many cases of organ transplantation it is not feasible to administer pharmacological agents to the donor. In a rat model of renal warm ischemia/reperfusion injury, preischemic and postischemic treatment with a nonselective ET antagonist resulted in improved renal function but pretreatment rendered better results than posttreatment. 24 In the postischemic setting, the ET A -RA was given just before reperfusion as we did in our study. We did not observe relevant changes in systemic hemodynamic parameters when ET A -RA BSF 208075 was given in a dose of 10 mg/kg body weight.
The surgical technique applied in our experimental model is fully adapted to the procedure in human pancreas transplantation. The UW solution, currently the "gold standard" in clinical pancreas transplantation, was used for organ FIGURE 3. Semiquantitative histologic score indices of the pancreatic grafts at different time points of procurement and after transplantation. Recipients were given endotholin A receptor antagonist (therapy group) or saline (control group). Score indices are calculated by means of score counts depending on the degree of tissue injury using 6 parameters (classification see Materials and Methods). The score indices of each group at each time of investigation are represented in the form of "box whisker plots" showing the median (line in box), the 25th and 75th percentiles (boxes) and the 95th percentiles (outer box). *Significant difference between control and therapy group (P Ͻ 0.05). Whereas histologic injury did not differ between the control and therapy group in the donors and before reperfusion, significantly less morphologic damage was seen at each measurement point after reperfusion in the group with endotholin A receptor antagonist therapy.
Witzigmann et al
Annals of Surgery • Volume 238, Number 2, August 2003 preservation. 29 The immunosuppression used in this setting was adapted from the study by Källén et al. 30 We decided to leave the recipient's pancreas in situ with the consequence that the endocrine function of the graft could not be evaluated. In a pilot study (unpublished data), we performed native pancreatectomy and allogeneic pancreas transplantation in 3 recipients. Technically, this operation is possible and euglycemia was attained in 2 of the 3 animals. The third became diabetic and died of abdominal infection. Native pancreatectomy would entail a prolonged operation time of 90-120 minutes and an additional major trauma, which does not correspond to the procedure in human pancreas transplantation. This trauma would greatly influence the parameters of ischemia/reperfusion injury measured in this study. Furthermore, these parameters indirectly represent the endocrine function, which is less susceptible to ischemia/reperfusion injury than exocrine function. 31 CRP is the most applied and best single marker for prediction of severity and prognosis in human genuine acute pancreatitis and graft pancreatitis. 27 TAP, which is not routinely used in the clinical setting, precedes the first peak of CRP and the systemic and clinical events of acute pancreatitis. 14, 15 In our study of experimental graft pancreatitis, treatment with an ET A receptor antagonist led to a significantly lower maximum systemic CRP but not TAP level. Further-more, we confirmed the slower rise of CRP as compared with TAP. Analogous to our results a study of acute necrotizing pancreatitis in rats and endothelin receptor blockade showed no difference in plasma TAP between treated and untreated animals. 6 The first peak of CRP at 36 hours with stable high levels until the fifth postoperative day corresponds precisely to the results in a study of human acute pancreatitis. 15 In accordance with the investigation in pigs by Benz et al 27 systemic lipase activity did not correlate with peak CRP. Impairment of microcirculation in the early reperfusion period is of major importance for the degree of graft pancreatitis in clinical pancreas the transplantation. 27 In this study, continuous tissue oxymetry was used to assess the microcirculation. Because we did not calculate oxygen consumption by the local tissue, p ti O 2 becomes possibly an unreliable indicator of microcirculation. However, this technique proved to be a valid method to detect rapid changes in nutritive capillary perfusion in a large animal model of warm pancreatic ischemia/reperfusion 3, 28 and in clinical pancreas transplantation. 27 In accordance with these studies, we found a steep increase of p ti O 2 in the control and therapy group within the first minutes after reperfusion, rapidly followed by capillary perfusion failure. Similar observations were made by Kubes in the intestine. 32 Therefore, we could not observe the "no reflow phenomenon," which is by strict definition a 33 Based on the present study using continuous tissue oxymetry the "no reflow phenomenon" seems to be the consequence of a short reperfusion period. During the short period of capillary perfusion after prolonged ischemia, the whole cascade of reperfusion events such as formation of oxygen free radicals and release of proinflammatory mediators is induced. However, as discussed above, it is a considerable benefit that during the transient capillary reperfusion after unclamping of the supply vessels there is a window for prophylactic treatment of microcirculation, which we used in our study design. Compared with the control group, prophylactic application of the selective ET A -RA led to significantly higher p ti O 2 values throughout the 5 day period of measurement and to levels that did not differ from the preischemic capillary perfusion. Likewise, a significantly better blood flow assessed by laser Doppler flowmetry was seen in the therapy group early after reperfusion. With this method, a differentiation between capillary perfusion and shunt flow is not possible. In both groups the blood flow was higher in the duodenum as compared with the corpus and tail of the pancreas, as reported in the studies by Schilling et al 34 and Studley et al. 35 The severity of graft pancreatitis, evidenced by the maximum CRP within 48 hours after reperfusion, revealed a clear association with impairment of microcirculation and grade of tissue injury. Other animal studies have demonstrated that pancreatic ischemia/reperfusion induced impairment of the microcirculation correlated with the evolving tissue injury and that improvement of microcirculation reduced tissue injury. 36, 37 We observed a significant reduction of tissue edema, parenchymal cell injury and inflammatory response by prophylactic application of a ET A -RA, which might be the result of decreased microcirculatory disturbances. The reduced edema strongly suggests that ET A receptor blockade diminishes capillary permeability as demonstrated in a study of experimental pancreatitis in rats. 10 Furthermore, the beneficial anti-inflammatory effect of ET A receptor inhibition shows clearly the proinflammatory role of ET-1 in ischemia/reperfusion injury. Similar results were found in a rat model of pancreas transplantation in which L-arginine caused an improvement of microcirculation and tissue injury. 37 In contrast, in a rat model of acute necrotizing pancreatitis delayed therapy with a nonselective endothelin receptor antagonist resulted in increased capillary blood flow without influence on acinar cell necrosis. 6 We analyzed for the first time the mRNA expression of selected cytokines, ET-1 and its ET A receptor with a quantitative RT-PCR in pig pancreatic tissue. The significantly higher intrapancreatic ET-1 mRNA and protein expression in the untreated group supports the hypothesis that ET-1 plays FIGURE 5. Immunohistochemical score indices of endothelin A receptor of the pancreatic grafts at different time points of procurement and after transplantation. Recipients were given endotholin A receptor antagonist (therapy group) or saline (control group). Score values are calculated by multiplication of mean values of intensity of immunostaining with the mean number of positive cells. The score indices of each group at each time of investigation are represented in the form of "box whisker plots" showing the median (line in box), the 25th and 75th percentiles (boxes) and the 95th percentiles (outer box). *, significant difference between control and therapy group (P Ͻ 0.05). ET A receptor expression was significantly higher 10 minutes, 1 hour, and 2 days after reperfusion in the control group as compared with the therapy group.
Annals of Surgery • Volume 238, Number 2, August 2003 an important role in the pathogenesis of graft pancreatitis. This finding is also in accordance with the significant increase of ET-1 plasma concentrations in the control group after reperfusion compared with the preoperative values. An inverse result was seen for the ET A receptor mRNA expression, whereas at the protein level the ET A receptor was, analogous to ET-1, increased in the control group. These findings are consistent with a recent study by Sonin et al showing markedly increased prepro-ET-1 and decreased ET A receptor expression after ischemia/reperfusion injury in the liver. 38 The increased ET A receptor mRNA expression in the therapy group could be a cellular mechanism to increase the sensitivity of the cell to ET-1 because the blockade is so effective that no ET-1 binds. However, in the control group where an undisturbed ligand-receptor interaction is possible we found decreased levels of ET A receptor mRNA. This may reflect a response of the vascular system maintaining the microcirculation through a desensitization of the cells. Controversial to this theory are the findings from the immunohistochemistry. It has been suggested that the splicing mechanisms of ET A receptor mRNA may constitute a post-transcriptional means of controlling the levels of active ET A receptors. There is evidence that splicing variants exist in which the exons 3 or 4 are excluded and a nonfunctioning receptor is synthesized. 39 It is possible that we detected these "cripple" recep-tors in the immunohistochemistry but we cannot detect the splicing variants with the PCR. The relevant higher IL-6 mRNA expression in untreated animals is consistent with the recent finding that ET-1 induces IL-6 release via activation of NF-B. 40 Furthermore, our data confirm the fact that IL-6 is the principal stimulus of the acute phase reaction, eg, synthesis of CRP. 41 In summary, ET-1 plays a central role in graft pancreatitis after pancreas transplantation. The present study clearly demonstrates that ET A receptor blockade significantly reduces the severity of graft pancreatitis by improving pancreatic capillary perfusion, which is associated with less tissue injury. Moreover, prophylactic application of the ET A -RA at the beginning of reperfusion might be the most effective approach. Based on these findings, future studies on the clinical application of endothelin receptor antagonists in pancreas transplantation would seem to be promising.
